European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union

Pharmaids Pharmaceuticals to acquire Adita Bio Sys in share swap

The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.

AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan

The deal includes upfront payments, milestone payments and ongoing royalties

Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA

Supriya Lifesciences received GMP certification from ANVISA Brazil

The clearance of this audit marks the successful registration of 8 APIs with CADIFA

PayNearby, Star Health join forces to provide health cover to uninsured across Bharat

Star Health's convenient claims process, valued added offerings like free telemedicine consultations with expert doctors

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US

CCRAS launches ‘SMART 2.0’ for ayurveda teaching professionals

Medway Hospitals raises US$5 million in a financing round led by Kyra Ventures

Medway setup a state-of-the-art Heart Institute in Chennai